Combined Influence Of Sod2 And Edn1 Genetic Polymorphisms On Chemotherapy-Related Cardiotoxicity Risk In Acute Leukemia Patients
Keywords:
Cardiotoxicity, Chemotherapy, Genetic PolymorphismsAbstract
Background: Chemotherapy-related cardiotoxicity is a serious complication in acute leukemia patients, with significant interindividual variability suggesting a genetic component. Polymorphisms in genes regulating oxidative stress and vascular tone, such as SOD2 and EDN1, may influence individual susceptibility.
Objective: To evaluate the impact of SOD2 C14510A and EDN1 Lys197Asn polymorphisms, both individually and in combination, on the risk of cardiotoxic complications in acute leukemia patients undergoing chemotherapy.
Methods: A clinical-genetic study included 102 acute leukemia patients (64 with cardiotoxicity, 38 without) and 97 healthy controls. Cardiotoxicity was defined by clinical, biomarker, and echocardiographic criteria. Genotyping was performed using PCR. Statistical analysis included allele/genotype frequency comparison and odds ratio calculation.
Results: The SOD2 A allele (34.3% in patients vs. 22.0% in controls; *p*<0.05) and A/A genotype (15.6% in cardiotoxicity subgroup vs. 5.2% without) were more frequent in patients with complications. The EDN1 Asn allele was also more common in patients with cardiotoxicity (28.1% vs. 22.4%). While individual polymorphisms showed non-significant trends toward increased risk (e.g., SOD2 A/A OR=3.46, *p*>0.05), combined carriage of SOD2 A and EDN1 Asn alleles was associated with a significantly higher frequency of cardiotoxicity (OR=3.26, 95% CI: 0.87–12.19, *p*=0.04).
Conclusion: The SOD2 A allele and EDN1 Asn allele are associated with an increased risk of chemotherapy-induced cardiotoxicity in acute leukemia patients. Their combined presence suggests an additive effect, highlighting the role of genetic predisposition in cardiotoxicity and supporting the integration of genetic markers into personalized risk assessment strategies.
References
Curigliano G., Cardinale D., Dent S., et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–325.
Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. Eur Heart J. 2016;37(36):2768–2801.
Armenian S.H., Lacchetti C., Barac A., et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers. J Clin Oncol. 2017;35(8):893–911.
Cardinale D., Biasillo G., Salvatici M., et al. Using biomarkers to predict and monitor cardiotoxicity of cancer therapy. Expert Rev Mol Diagn. 2017;17(3):245–256.
Visscher H., Ross C.J., Rassekh S.R., et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422–1428.
Wang X., Sun C., Liu H., et al. Genetic variants associated with cardiotoxicity induced by anthracyclines: A systematic review and meta-analysis. Pharmacogenomics J. 2021;21(2):152–163.
Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., et al. Structural dimorphism in the mitochondrial targeting sequence of human manganese superoxide dismutase. Biochem Biophys Res Commun. 1996;226(2):561–565.
Wojnowski L., Kulle B., Schirmer M., et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with anthracycline-induced cardiotoxicity. Circulation. 2005;112(24):3754–3762.
Semsei A.F., Erdelyi D.J., Ungvari I., et al. Polymorphisms in antioxidant genes are associated with cardiomyopathy in childhood acute lymphoblastic leukemia. Free Radic Biol Med. 2012;52(8):1602–1609.
Battistini B., Berthiaume N., Kelland N.F., et al. Profile of endothelin receptors and their antagonists in cardiovascular disease. Pharmacol Rev. 2006;58(3):434–463.
Tiret L., Poirier O., Nicaud V., et al. Polymorphism of the endothelin-1 gene and coronary heart disease in the ECTIM study. Hypertension. 1999;33(1):76–80.
Ahmed A.M., El-Hefnawy M.H., El-Sherbiny S.M., et al. Association of EDN1 rs5370 polymorphism with cardiovascular disease risk. J Clin Hypertens. 2020;22(7):1234–1241.
Sawyer D.B., Peng X., Chen B., et al. Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105–113.
Lenneman C.G., Sawyer D.B. Cardio-oncology: An update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008–1020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kayumov A.A., Zokirova M.B.
This work is licensed under a Creative Commons Attribution 4.0 International License.
